After Glenmark Pharma and Hetero Labs, Cipla has now introduced generic medicine of Remdesvir for corona patients. The company has named the drug Cipremi. It has been approved by the US drug regulator USFDA to provide Covid-19 patients in an emergency. There is currently no information about the price of the drug.
Cipla also gets permission from DCGI
Remdesvir is the only drug the USFDA has approved for emergency use for the treatment of patients with COVID-19. Gilead Sciences signed a non-exclusive agreement with Cipla in May for manufacturing and marketing Remedesivir. Cipla said that it has received limited permission from the Controller General of India (DCGI) for emergency use of the drug in an emergency.
Supply will be done through government and open market
The company said that this drug will be supplied through the government and the open market. Cipla Ltd Managing Director Global CEO Umang Vohra said, “Cipla appreciates the strong partnership with Gilead Sciences for the treatment of patients in India. We have invested heavily in exploring all possible ways to save the lives of millions affected by the Covid-19 pandemic and this offering is an important step in that direction. ‘
Hetero Labs has launched Covifor
Earlier on Saturday, the Central Drugs Standard Control Organization (CDSCO) allowed Hetero Labs to manufacture and supply generic versions of Remdesivir. Hetero Labs will sell this drug under the name of ‘Covifor’ in India.
Glenmark Pharma launches Fabi Flu
Glenmark Pharmaceuticals has also developed a corona drug. The company has launched the antiviral drug Fabi Flu for patients with mild to moderate corona. This drug has also received approval from DCGI.
Remedisvir very successful in corona treatment
Remedesivir drug Corona treatment is considered to be very successful. American pharma company Gilead Sciences is a patent holder of Remdesvir. Cipla and Hetero Labs are in a non-exclusive licensing agreement with Gilead Sciences.